Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digital Platform Caresyntax Extends Series C To Total $130M Raised

Executive Summary

Caresyntax raised $130m in total funding to expand commercialization of its software that seeks to reduce variability and improve outcomes in the operating room.

You may also be interested in...



Digital Health Roundup, April 2021: Digital Transformation In OR, Clinical Trials, Remote Monitoring

In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from April.

De Oro Devices’ Nex(t)Stride To Help Freezing Gait Is Expand Into Other Diseases, Add Software

De Oro Devices’ plans to add more indications for its portable device for freezing gait associated with Parkinson’s disease. In 2023, the company hopes to address , multiple sclerosis, stroke and cerebral palsy, and add mobility-gait software.

MedRhythms On First-To-Market Track With Prescription Music Therapy For Chronic Stroke

MedRhythms’ digital therapeutics platform aims to improve walking and functional outcomes in patients with multiple sclerosis, Parkinsons’ disease and chronic stroke. With around $32m in funding to date, the start-up boasts collaborations with major medical centers and a partnership with Biogen.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT144479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel